Article Text

Download PDFPDF

Short report
Bronchoconstriction following nebulised colistin in cystic fibrosis


Nebulised colistin is regularly used as antipseudomonal therapy in children with cystic fibrosis. We assessed bronchoconstriction in response to nebulised colistin in 58 children. Nebulised colistin significantly reduced FEV1, MEF25%, and Sao 2 for 15 minutes. In 20 children the reduction was greater than 10% from baseline FEV1, and was still at that level in five at 30 minutes. Subjective assessment, baseline FEV1, and serum IgE were unable to identify susceptible children. It is recommended that children receiving colistin should be carefully assessed for bronchoconstriction.

  • cystic fibrosis
  • colistin
  • bronchoconstriction

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Nebulised antibiotic therapy is considered to have significant impact on long term pulmonary morbidity in patients with cystic fibrosis (CF) colonised with Pseudomonas aeruginosa.1 Although a number of antibiotics can be nebulised, colistin is a popular choice in European centres, primarily because of the Danish evidence supporting its use. Colistin sulphomethate is a polymyxin antibiotic that is preservative free; it is produced as a dry powder preparation which is reconstituted with saline prior to nebulisation.

Studies in adults have shown bronchoconstriction in response to nebulised colistin2; however, to date no study has identified the extent of the problem in children. We therefore sought to identify the frequency of bronchoconstriction following nebulised colistin, its duration of effect, and its relation to subjective feelings of chest tightness.


The study was a prospective cross sectional assessment of children attending three large paediatric CF clinics in London, UK. Children (>5 years of age) who were regular or first time users of nebulised colistin were asked to participate in the study, and were asked not to use any bronchodilator for at least six hours prior to the study. Spirometry was performed immediately before nebulisation of a standard dose of colistin made up to a total of 4 ml volume with 0.9% saline (<7 years 0.5 megaunit, ⩾7 years 1 megaunit). Spirometry was performed using a compact spirometer (Vitalograph, Buckingham, UK). Colistin was administered by either Pari LC star (Pari, Starnberg, Germany) or Ventstream (Medic-Aid, Pagham, Sussex, UK) nebulisers and either Portaneb (Medic-Aid, Pagham, Sussex, UK) or Pariboy (Pari, Starnberg, Germany) compressors. Further spirometry was performed immediately following the cessation of nebulisation and then at 15 minutes post nebulisation. Children with bronchoconstriction at 15 minutes had further spirometry performed at 30 minutes. Polgar standards have been used where age/sex related values of spirometry are quoted.3 Following nebulisation, children were asked to give a subjective appraisal of whether or not they felt chest discomfort in association with the treatment.

Descriptive statistics report mean (standard deviation) unless otherwise stated. Percentage changes are relative to baseline, and not a percentage fall of predicted. Student's ttests were used to assess change in spirometry before and after nebulisation and also changes in relation to subjective discomfort. Spearman correlation was used to test the association between age and recent serum IgE value with changes in spirometry.

Ethical approval was obtained from the local ethical committee at each of the three hospitals participating. Informed consent was obtained from parents and children prior to each study.


A total of 58 children were studied with a mean age of 12.0 (3.1) years (range 5.1–17.4). Fifty five children were regular colistin users (41 for more than two years); three were using colistin for the first time. Mean FEV1 before colistin was 59.3% (18.3%).

Colistin was associated with a significant fall in FEV1 in the group as a whole at 0 (mean 5.9% (9.6%), p < 0.001) and 15 (mean 3.3% (10.2%), p < 0.004) minutes post nebulisation. Twenty children (34%) had more than 10% reduction in FEV1; these children had a mean decrease in FEV1 of 17.8% (5.9%), with a maximum fall of 37.5%. The time to maximum fall in FEV1 was 0 minutes in 13, 15 minutes in five, and 30 minutes in two patients. Five children (9%) continued to have an FEV1 at 10% above baseline at 30 minutes (see fig 1). In the group as a whole there was also a significant reduction in MEF25% at 0 (mean reduction 12.2% (35.0%), p = 0.003) and 15 (mean 10.5% (37.6%), p < 0.001) minutes, and a reduction in oxygen saturation at 0 (mean 0.6% (1.3%), p < 0.001) and 15 (mean 0.4% (1.2%) p = 0.023) minutes. Sixteen children (28%) had a reduction in oxygen saturation of at least 2% following nebulised colistin (maximum reduction 4%).

Figure 1

Change in FEV1 from baseline with nebulised colistin.

No significant correlation was found between age, serum IgE, or baseline FEV1 and changes in FEV1, MEF25%, or Sao 2 at 0, 15, and 30 minutes. No significant difference was found for changes in spirometry post nebulisation between those patients experiencing chest discomfort in association with nebulisation (n = 9, p = 0.15), or those with current symptoms of respiratory tract infection (n = 10, p = 0.85).


This study has shown significant bronchoconstriction in one third of children receiving nebulised colistin in our clinics. This bronchoconstriction was persistent (30 minutes) in 9%, and was associated with a fall in oxygen saturation in some children. Atopic tendency, baseline FEV1, and subjective assessment were not able to identify those children with significant bronchoconstriction.

Nebulised colistin has previously been reported as inducing bronchoconstriction in adult patients2: this effect was independent of the tonicity of the solution nebulised. Two studies have assessed bronchoconstriction in response to nebulisation of the intravenous preparation of tobramycin in groups of 124 and 265 CF patients. The latter study showed bronchoconstriction in 19% of patients immediately following nebulisation; however, they did not address time to minimum FEV1 or time to recovery. A new preparation of tobramycin (TOBI, PathoGenesis, Seattle, USA) has been reported as having no significant bronchoconstriction; however, patients were only studied at 30 minutes and some bronchoconstriction was evident at that time, though it is unclear in how many patients.6 The cost of this new tobramycin preparation, however, will possibly limit its use in Europe and colistin will most likely remain the first choice nebulised antibiotic in the paediatric age group. It is important therefore that users are aware of the potential bronchoconstriction that may be induced by this antibiotic. Children should be tested for bronchoconstriction with first administration of colistin; in younger children who are unable to perform spirometry, the use of bronchodilator premedication is recommended.


We acknowledge Adriana Machin, senior physiotherapist, Royal Brompton & Harefield NHS Trust, and Gail Slade and John Martin, respiratory technicians, Great Ormond Street Hospital.


Linked Articles